# A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke

Study · id `cardio:ct-nct05884502` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05884502](<https://clinicaltrials.gov/study/NCT05884502>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05884502

Browse, organ or system: Brain; Metabolism  
Browse, condition area: Risk and prevention; Stroke; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 330 participants.

## Technical summary

Registry record NCT05884502. Randomized; no masking; primary purpose treatment. Start 2022-09-01 (actual); primary completion 2023-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 330 participants (planned count; ClinicalTrials.gov record NCT05884502, source copy `cardio:ctgov-nct05884502-2023-06-01`, retrieved 2026-10-26)
- Started: 2022-09-01 (actual) (ClinicalTrials.gov record NCT05884502, source copy `cardio:ctgov-nct05884502-2023-06-01`, retrieved 2026-10-26)
- Primary completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05884502, source copy `cardio:ctgov-nct05884502-2023-06-01`, retrieved 2026-10-26)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05884502, source copy `cardio:ctgov-nct05884502-2023-06-01`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05884502, source copy `cardio:ctgov-nct05884502-2023-06-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05884502-2023-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke
- Condition: Dyslipidemias
- Condition: Stroke, Acute Ischemic
- Intervention (Drug): combination of high-dose rosuvastatin and ezetimibe
- Intervention (Drug): high-dose rosuvastatin single administration
- Lead sponsor: Korea University Anam Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Korea University Anam Hospital (`cardio:org-korea-university-anam-hospital`)

## Provenance

Content hash: 25a3441338a17ee51aacb98e8a7a2e19bed8c5f2e42384b460ef34de53ee5737
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
